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Abstract
A comparative study of combined Tamiflu and BioR treatment has been performed in 22 patients with (H1N1) influenza A (the experimental lot) and 
17 patients (the control lot) in which only the Tamiflu was administered.  The diagnosis of influenza A (H1N1) was confirmed using PCR.  The clinical 
symptomatology varied amongst patients, but the most frequent symptoms were fever, throat pains asthenia, myalgias, hyperemia of the pharyngeal 
isthmus, dry cough, harsh respiration, chills, and nasal congestion.  Tamiflu was administered in a dose of 75 mg orally twice a day, in the morning and 
in the evening; the average length of treatment was 5 days.  BioR was administered to 16 patients as 5.0 mg orally, twice a day, and to 6 patients as1 mg 
IM, twice a day; average length of treatment was 5 days for all groups.  The control group received Tamiflu only, the same dosage as the study group. 
The average length of treatment was 6.0 days.  Comparing the length of the symptoms in the experimental group to that in the control group, we found 
that duration of symptoms reflecting the influence of the central nervous system in the experimental group was on average 5.0 days as compared to 6.6 
days in the control group. Similarly, duration of symptoms affecting the respiratory system in the experimental group was 3.8 days and in the control 
group 5.3 days.  We conclude that the Tamiflu and BioR treatment in patients with influenza A (H1N1) was beneficial and contributed to the decrease 
of symptom duration as compared to the group of patients treated with Tamiflu alone.  
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Комбинированное лечение Тамифлу и БиоР у больных гриппом А (H1N1)
Было изучено эффективность комбинированного лечения Тамифлу и БиoРом у 22 больных гриппoм А (H1N1), экспериментальная группа, 
и 17 больных, контрольная группа, которые получали только Тамифлу.  Диагноз гриппа А (H1N1) был установлен биомолекулярным методом 
(ПЦР).  Клиническая симптоматология была многообразная, но самые частые симптомы, которые встречались у обеих групп, были: лихорадка, 
боли в горле, слабость, боли в мышцах, гиперемия зева, сухой кашель, ознобы и гиперемия лица.  Тамифлу был назначен в дозе 75 мг 2 раза 
в день утром и вечером, длительность лечения в среднем составляло 5,0 дней.  БиoР был назначен в дозе 5 мг 2 раза в день перорально у 16 
больных, и по 1,0 мг в/м 2 раза в день у 6 больных.  Длительность лечения составила 5 дней.  В контрольной группе был назначен только 
Тамифлу в такой же дозировке как в первой группе.  Длительность лечения составила 6 дней.  При сравнении длительности симптомов в 
экспериментальной и контрольной группе было отмечено, что симптомы характерные для поражения нервной системы сохранялись в среднем 
5,0 дней, а в контрольной группе 6,6 дней, а симптомы поражения верхних дыхательных путей соотвественно – 3,8 и 5,3 дней.  Комбинированное 
лечение Тамифлу и БиоРом в сравнении с лечением только Тамифлу привело к сокращению длительности клинической симптоматики и к 
уменьшению периода госпитализации больных гриппом и больных бронхопневмонией.
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Introduction
In April 2009 cases of contagious, acute respiratory disease 
in the USA (South California and Texas) were first registered 
as an influenza A virus of a new type called H1N1.  The new 
virus appeared suddenly and was simultaneously identified 
in 2 other countries, Mexico and Canada.
The situation with the infection of a new viral influenza 
A (H1N1) developed rapidly, affecting in a short period of 
time a great number of people from all continents.  These 
events forced the WHO to raise on 11 June 2009 the level of 
pandemic alert from place 5 to 6, which meant the beginning 
of the first influenza pandemia in the 21st century.  
Influenza, as well as other respiratory diseases, generates 
important economical losses every year, with associated costs 
of medical care, decreased ability to work throughout the du-
ration of infection – either of an affected adult or one taking 
care of an affected child.  The greatest part of expenditures 
of medical care constitutes the hospitalization costs.  About 
14.6 billion dollars are spent every year throughout the world 
to treat influenza and its complications.  A single person, in 
turn, can spend the equivalent of 30-100 Moldovan den on 
the influenza infection, covering the cost of treatment post 
influenza complications – which, depending on severity, can 
easily amount to a  cost of $100 American dollars.  
For effective results, influenza treatment should be started 
as soon as possible within 2 days from the first signs of influ-
enza.  Tamiflu (oseltamivir) has been shown to be the most 
efficient, reducing the complications rate by 55%. It acts as a 
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neuraminidase inhibitor, preventing cleavage of  budding viral 
progeny and instead fixing the virus to the host cell.  
The toxic action of the influenza virus includes inhibition 
of cellular and humoral immunity, resulting in diminished 
the resistance.  The native preparations such as BioR are of 
a particular interest which have a large spectrum of action: 
immunomodulatory, immunostimulatory, antiviral, cytopro-
tector and regenerant.
Due to these aspects we designed a study with BioR to 
evaluate its role as a therapeutic agent in influenza treatment.
Material and Methods
The study included 22 patients (the study group) from 19 
- 68 years of age (the average age was 33.6 ± 0.9) comprised 
of males – 10 (45.5%), females – 12 (54.5%). There was an 
equal split between patients residing in urban vs rural areas. 
Twelve patients were addressed to the family doctor and/or 
emergency personal and ten presented independently to the 
admission rooms of CHID- “T. Ciorba”. Eight patients were 
admitted in the first 2 days, eleven on days 3- 5, two on days 
7- 8  and one on the 13th day.  The length of hospitalization 
was 5 days for 20 patients, 8 days for 1 and 9 days for 1 patient 
(the average length was 5.09 ± 0.01 days).
17 patients were enrolled into the control group, they 
were from 19 - 51 years of age (the mean age was 25.6 ± 1.2), 
comprised of men - 8 (47.1%), women – 9 (52.9%). Eight were 
from an urban area (47.1%), and 9 (52.9%) patients were from 
a rural area (p > 0.05).  Four patients were initially seen by 
their family doctor, nine by the emergency medical personal, 
and five patients came independently to the admission room 
at “T. Ciorba”.  12 patients were seen in the first day of the 
disease, the other five patients were admitted on the 10th day. 
The hospitalization length was 5 days for 9 patients, 6 days 
for 2, 7 days for 4, 9 days for 1 and 10 days for 1 patient (the 
mean length of hospitalization was 6.1 days).  The diagnosis 
of influenza A (H1N1) was confirmed by PCR in all of the 
patients included in the study. In the control group, PCR 
confirmed results were available on the first day of the disease 
in 1 patient, on the 2nd day in 4 patients, on the 3rd day in 4, 
on the 7th day in 5, on the 6th day in 2 and on the 9th day in 1 
patients.  In the experimental group, PCR confirmed H1N1 
on the 1st day in 1 patient, on the 2nd day in 4, on the 3rd day 
in 3, on the 4th day in 5, on the 6th day in 5, on the 7th day in 2 
and on the 9th day in 1 patient).
Table 1
Clinical symptomatology in patients of A (H1N1) influenza the study lot and control lot
      Symptoms 
The study group  22 patients The control group  17 patients
χ2 p
Abs. P1±Es1 The length of symptoms Abs. P2±Es2
The length of 
symptoms
Cephalagia 18 81,8±8,2 4,5 11 64,7±11,6 6,4 4,53 **
Ocular pains 6 27,3±9,5 3,7 3 17,6±9,2 4,2 5,25 **
Myalgias 13 59,1±10,5 5,0 7 41,2±11,9 5,6 7,79 ***
Arthralgias 8 36,4±10,3 4,2 4 23,5±10,3 4,8 7,00 ***
Asthenia 10 45,5±10,6 6,8 14 82,4±9,2 7,7 16,53 ****
Chills 8 36,4±10,3 3,4 5 29,4±11,1 3,2 1,64 *
Fever < 38ºC 9 40,9±10,5 7,6 6 35,3±11,6 7,5 0,89 *
Fever > 38ºC 13 59,1±10,5 5,0 11 64,7±11,6 6,2 0,49 *
Nasal congestion with choriza 3 13,6±7,3 4,3 8 47,1±12,1 5,2 23,74 ****
 Throat pain 16 72,7±9,5 4,2 12 70,6±11,1 4,8 0,06 *
Fascies tumefied 1 4,5±4,4 1,0 5 29,4±11,1 4,8 21,02 ****
 Fascies  congested 8 36,4±10,3 3,2 7 41,2±11,9 4,0 0,56 *
Injected scleare 2 9,1±6,1 4,5 5 29,4±11,1 4,8 14,04 ****
Lacrimations 2 9,1±6,1 3,5 6 35,3±11,6 4,6 19,45 ****
Hyperemia of the pharynx 20 90,9±6,1 5,9 17 100,0±0,0 6,2 0,83 *
Chest pains 10 45,5±10,6 3,0 2 11,8±7,8 4,0 96,48 ****
Dyspnoea 3 13,6±7,3 6,2 17 100,0±0,0 8,6 74,59 ****
Dry rales 6 27,3±9,5 4,2 5 29,4±11,1 6,8 0,16 *
Moist rales 4 18,2±8,2 8,0 2 11,8±7,8 8,0 3,50 *
Crepitant rales 3 13,6±7,3 3,3 1 5,9±5,7 6,0 10,22 ***
Harsh breathing 17 77,3±8,9 5,7 10 58,8±11,9 6,6 5,79 **
Attenuated breathing 3 13,6±7,3 3,0 1 5,9±5,7 4,0 10,22 ***
Nausea 4 18,2±8,2 2,5 5 29,4±11,1 2,6 4,29 **
Vomiting 5 22,7±8,9 2,0 4 23,5±10,3 2,7 0,03 *
Watery diarrhea 1 4,5±4,4 1,0 3 17,6±9,2 1,5 9,73 ***
Tachycardia 5 22,7±8,9 3,5 3 17,6±9,2 4,3 1,46 *
Bronchopneumonia 5 22,7±8,9 6,2 5 29,4±11,1 6,6 1,52 *
Bronchitis 18 81,8±8,2 - 4 23,5±10,3 - 144,40 ****
Changes of the ECG 4 18,2±8,2 - 1 5,9±5,7 - 25,72 ****




The changes in leukogram  in patients of A (H1N1) influenza, the study lot and control lot
The leukogram
The study lot Control lot
χ2 p
Abs. P1 ± Es1 Media Abs. P2 ± Es2 Media
Leukopenia 5 22,7 ± 8,9 3,1 1 5,9 ± 5,7 3,9 48,24 ****
Leukocytosis 0 0,0 0 0 0,0 0 - -
Normocytosis 17 77,3 ± 8,9 5,9 16 94,1 ± 5,7 5,6 3,01 *
Left deviation 21 95,5 ± 4,4 22,0 13 76,5 ± 10,3 19,6 4,71 **
Lymphocytosis 5 22,7 ± 8,9 42,5 5 29,4 ± 11,1 56,8 1,52 *
Lymphopenia 5 22,7 ± 8,9 11,5 0 0,0 0 - -
Monocytosis 10 45,5 ± 10,6 16,1 8 47,1 ± 12,1 17,3 0,05 *
VSH increased 7 31,8 ± 9,9 30,4 7 41,2 ± 11,9 24,2 2,13 *
p > 0.05 **p < 0,05 **** p < 0.001.
Table 3
Antibiotic treatment in the study and control groups for patients with A (H1N1) influenza
Antibiotics
The study lot Control lot
No of patients  Dose Duration of treatment No of patients  Dose Duration of treatment
Cephalosin 4 1,0x2 td 3,5 days 3  1,0x3 td 5,6 zile
Ceptriaxin 4 1,0x3 td i.m. 7,5 days 1  0,25x2 td 2,0
Cephexim 1 1,0x2 td 4,0 days -  - -
Cepin 2 1,0x2 td 4,5 days -  - -
Azitromycin 4 500,0x1 td 3,0 days -  - -
Ampicillin 3 1,0x3 td 6,0 days 1  150mgx3 td 4,0
Amoxicillin 5 1,0x2 td 4,5 days 10  1,0x3 td 4,0
Augumentin 2 1,2x2 td 4,5 days -  - -
Ciprinol 1 400mgx2 td 4,0 days -  - -
Oxacyllin - - - 1  0,4x4 td i.m. 5.0
Results and discussions
This study evaluated a wide range of clinical symptoma-
tology in the enrolled patients, presented in tab. 1.
Analysing table 1, we can see  multiple clinical symp-
toms in both groups, affecting the central nervous system, 
respiratory and cardiovascular systems.  The most frequent 
symptoms were fever(100% in the first lot and 100% in the 
second one), throat pains (72,7% and 70,6%), asthenia (45,5 
% and 82,4%) myalgias (59,1% and 41,2%), hyperemia of the 
pharyngeal isthmus (90,9 % and 100 %),  harsh breathing (77,3 
% and 58,8%), chills (36,4 % and 29,4%), fascies congested 
(36,4% and 41,2%). 
When comparing the length of clinical symtoms in the 
study group and the control group we come to the conclu-
sion that the length of the symptoms reflecting the affected 
central nervous system in the study group was on average 5,0 
days, while in the control the average was of 6,6 days. With 
respect to the symptoms affecting the respiratory system, 
duration was 3,8 days  in the experimental grouo and 5,3 in 
the control group.
Bronchopneumonia occurred at the same frequency in 
both groups in 5 patients. The length of hospitalization with 
bronhopneumonia in the experimental group was on average 
5,2 days and in the control group 7,0 days.
The changes in leukogram are listed in table 2. 
According to the data from table 2, leukocytosis is not 
characteristic for viral infections and leukopenia was revealed 
only in 5 patients from the experimental group and in one 
patient from the control group.  Normocytosis was revealed 
more frequently (77.3 % and 94.1 %), left deviation (95.4 % 
and 76.7%) and monocytosis (45.4 % and 47.1%).
Treatment
Treatment of patients from the study group was an anti-
viral, Tamiflu, combined with an immunomodulatory BioR. 
Treatment for the control group was with Tamiflu and placebo.
Tamiflu was administered in a dose of 75 mg orally twice 
a day, in the morning and in the evening after meals.  The 
duration of treatment was 5 days in 15 patients, 6 days in 5 
patients, 9 in 1 patients and 10 days for 3 patients. The average 
length of treatment was 5 days. 
BioR was administered in a dose of 5 mg orally twice a day 
in the morning and in the evening in 16 patients and 1 ml. IM 
twice a day for 5 days in 6 patients.  The patients from control 
group were given the Tamiflu only in a dose of 75 mg orally 
twice a day in the morning and in the evening.  The duration 
of treatment was 5 days for 9 patients, 6 days for 4 patients, 7 
days for 2 and 10 days for 1 patients the average being 6 days.
Taking into account that the toxic action of influenza 
virus inhibits both cellular and humoral immunity, leading 
to attenuation of local resistance and increased susceptibility 
to infection with bacterial foci in trachea, bronchi and lungs, 
an antibiotic treatment was administrated as shown in tab. 3.
According to the information in table 3, cephalosporins, 
macrolides, B-lactams and fluoroquinolones were used in the 
treatment of patients with the influenza virus.  Only one patient 
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from the control group was not administered antibiotic treat-
ment.  The length of antibiotic treatment in the study group 
was 4.0 while in the control group it was 4.5 days.
Pathogenic and symptomatic treatment
Both groups received some maintenance therapy. In 9 
patients this included glucose 5%, physiological serum 0.9%, 
haemodesia and arginine in 1 patient, antipyretics in 15 
patients, vitamins (ascorutin) in 29 patients, desensitizers 
in 15 patients, expectorants in 6 patients, broncholytics in 7, 
antitussives in 8, respiratory analeptics in 6, vasoconstrictive 
decongestants in 8, diuretics and corticosteroids in one pa-
tient for a day.
Conclusions
Treatment with Tamiflu and BioR in patients with A 
(H1N1) influenza was beneficial and contributed to:
· Reduction by an average of one day in the length of 
symptoms that affected the central nervous system, and 
particularly those reflecting the action of the sympa-
thetic nervous system,
· Reduction of symptoms affecting the respiratory system 
(3.8 days in the experimental group and 5.3 days in the 
control one).
· Decreased hospitalization length in patients with influ-
enza A (H1N1) (5.09 days in the experimental group 
and 6.1 in the control group).
· Decreased hospitalization length of patients with bron-
chopneumonia in the experimental group (5.2 days vs 
7 days)
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Abstract
Tooth loss compromises human oral health.  Although several prosthetic methods (such as artificial denture and dental implants) are clinical therapies 
to tooth loss problems, they are thought to have safety and usage-time issues.  Recently, tooth tissue engineering has attracted more and more attention. 
Stem cell based tissue engineering is thought to be a promising way to replace the missing tooth.  Mesenchymal stem cells (MSC) are multipotent stem 
cells which can differentiate into a variety of cell types.  The potential MSC for tooth regeneration mainly include stem cells from human exfoliated 
deciduous teeth, adult dental pulp stem cells, stem cells from the apical part of the papilla, stem cells from the dental follicle, periodontal ligament stem 
cells and bone marrow-derived mesenchymal stem cells.  This review outlines the recent progress in mesenchymal stem cell research and its use in tooth 
regeneration and oral and craniofacial applications.
Key words: mesenchymal stem cell, tooth engineering, dental pulp stem cell.
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